Dangaj lab
Our main goal is to understand tumor-intrinsic and extrinsic mechanisms that promote or dampen anti-tumor T cell immunity. To that end, my group explores the molecular states of tumor-infiltrating lymphocytes (TILs) and the tumor microenvironment (TME) at various stages of tumor rejection or escape, the mechanisms of TIL exclusion and dysfunction in the TME, the role of cancer cell genomic alterations and heterogeneity in regulating the inflammation status of TILs in tumors and the development of autologous 3D TME and systems immunology models to evaluate TIL reactivity for adoptive cell therapies. ...
Research projects
Please check back later to discover our ongoing projects.
Latest publications
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma.
Barras D, Ghisoni E, Chiffelle J, (...), Harari A, Laniti DD, Coukos G
Science immunology – 2024 Feb 2
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S, Bianchi V, Tanyi JL, (...), Kandalaft LE, Harari A, Coukos G
Nature Cancer – 2023 Sep 21
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J, Turrini R, Minasyan A, (...), Doucey MA, Dangaj Laniti D, Coukos G
Cancer cell – 2021 Nov 4
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.
Lanitis E, Kosti P, Ronet C, (...), Dangaj Laniti D, Coukos G, Irving M
Journal for immunotherapy of cancer – 2021 Aug 20
Team
Denarda Dangaj
Group leader, Human integrated tumor immunology discovery engine (Hi-TIDe), Department of Oncology UNIL & CHUV, Ludwig Institute for Cancer Research Lausanne
denarda.dangaj@chuv.chOther members
Selected Publications
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera FG, Ronet C, Ochoa de Olza M, (...), Dangaj Laniti D, Irving M, Coukos G
Cancer discovery – 2021 Sep 3
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.
Lanitis E, Kosti P, Ronet C, (...), Dangaj Laniti D, Coukos G, Irving M
Journal for immunotherapy of cancer – 2021 Aug 20
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M, Barras D, Mina M, (...), Martinon F, Dangaj Laniti D, Coukos G
Cell reports – 2021 Jul 20
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
Baumgaertner P, Sankar M, Herrera F, (...), Xenarios I, Guex N, Harari A
Frontiers in immunology – 2021 Apr 30
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
Lanitis E, Rota G, Kosti P, (...), Dangaj D, Coukos G, Irving M
The Journal of experimental medicine – 2021 Feb 1
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams SF, Grimm AJ, Chiang CL, (...), Coukos G, Gimotty PA, Kandalaft LE
Journal for immunotherapy of cancer – 2020 Aug 20
Tumor Landscapes: β-Catenin Drives Immune Desertification.
Dangaj D, Barras D, Coukos G
Clinical cancer research : an official journal of the American Association for Cancer Research – 2019 Mar 5
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi JL, Bobisse S, Ophir E, (...), Harari A, Coukos G, Kandalaft LE
Science translational medicine – 2018 Apr 11
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S, Genolet R, Roberti A, (...), Kandalaft LE, Coukos G, Harari A
Nature communications – 2018 Mar 15
Mechanisms regulating T-cell infiltration and activity in solid tumors.
Lanitis E, Dangaj D, Irving M, Coukos G
Annals of oncology : official journal of the European Society for Medical Oncology – 2017 Dec 1
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith JB, Lanitis E, Dangaj D, (...), Stashwick C, Scholler N, Powell DJ Jr
Molecular therapy : the journal of the American Society of Gene Therapy – 2016 Jul 21
Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.
Zsiros E, Dangaj D, June CH, Kandalaft LE, Coukos G
Oncoimmunology – 2015 Oct 19
Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.
Dangaj D, Scholler N
Oncoimmunology – 2013 Jul 31
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.
Lanitis E, Dangaj D, Hagemann IS, (...), Sandaltzopoulos R, Coukos G, Powell DJ Jr
PloS one – 2012 Nov 26
Related news
Events
AGORA Sustainability Day | May 1st
Events
AGORA PRS | March 19th
Events
AGORA PRS | March 7th
Events
AGORA PRS | February 28th
Events
